Paratek Pharmaceuticals, Inc.
PRTK
PRTK was delisted on the 20th of September, 2023.
66 hedge funds and large institutions have $47M invested in Paratek Pharmaceuticals, Inc. in 2023 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 12 increasing their positions, 19 reducing their positions, and 17 closing their positions.
24% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 17
5% more funds holding
Funds holding: 63 → 66 (+3)
20% less capital invested
Capital invested by funds: $59M → $47M (-$12M)
37% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 19
44% less call options, than puts
Call options by funds: $146K | Put options by funds: $260K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NM
Newtyn Management
New York
|
+$1.59M |
| 2 |
EP
Eversept Partners
New York
|
+$1.43M |
| 3 |
N
Natixis
Paris,
France
|
+$1.02M |
| 4 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$994K |
| 5 |
Two Sigma Investments
New York
|
+$822K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$6.79M |
| 2 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$5.01M |
| 3 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$1.67M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$935K |
| 5 |
Morgan Stanley
New York
|
-$426K |
PRTK Hedge Fund Activity: Q2 2023 in Review
66 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q2 2023, worth a combined $47M — down 20% from $59M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new PRTK positions and 17 closed out — a net gain of 4 holders — while 12 added to existing stakes and 19 trimmed.
The largest buyer was Newtyn Management, opening a new position worth an estimated $1.59M. The largest seller was AIGH Capital Management, exiting entirely with an estimated $6.79M sold.
- 66 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q2 2023, up from 63 in Q1 2023.
- Funds reported $47M of Paratek Pharmaceuticals, Inc. stock for Q2 2023, down 20% quarter-over-quarter.
- 21 funds opened new Paratek Pharmaceuticals, Inc. positions in Q2 2023 and 17 closed out, a net change of +4 holders.
- The largest Paratek Pharmaceuticals, Inc. buyer in Q2 2023 was Newtyn Management, an estimated $1.59M added.
- The largest Paratek Pharmaceuticals, Inc. seller in Q2 2023 was AIGH Capital Management, an estimated $6.79M sold.
Based on aggregated 13F filings for Q2 2023.